The European Medicines Agency is due to decide this week whether to fast track its review of the planned EU marketing applications for two products – spesolimab, from Boehringer Ingelheim, and BridgeBio Pharma’s fosdenopterin.
Meanwhile, Astellas Pharma/Seagen’s urothelial cancer drug, enfortumab vedotin, has lost the fast-track status it was granted in February...








